Genome Research Technology Offers

Yissum - Research Development Company of the Hebrew University posted this:

Diagnosis & Rehabilitation of Language Disorders in Children, Using a Self-Operated Tablet Based App Diagnosis & Rehabilitation of Language Disorders in Children, Using a Self-Operated Tablet Based App Project ID : 19-2019-8746

Yissum - Research Development Company of the Hebrew University posted this:

Enhanced Secretion of Proteins by Tag-Cleaving Cellular System Enhanced Secretion of Proteins by Tag-Cleaving Cellular System Project ID : 6-2019-8747

LUCIA CORAL posted this:
Knowledge Tranfer Manager at National Cancer Institute CRO Aviano

Predictive Kit to identify patients non responding to platinum therapy Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types. The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treatment at higher risk of developing drug resistance and disease progression. Drugs such as cisplatin, oxaliplatin and carboplatin are used to treat various types of worldwide common cancer, but resistance is a frequent event. Patient stratification based on tumor gene expression profile allows to personalize treatment reducing side effects and costs.

University of Granada (OTRI) posted this:

Method for diagnosing Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT) is a rare and genetic disease in which a disorder in angiogenesis exists. A new method for the molecular diagnosis of this disease has been developed. It is based on the quantification of a set of microRNAs (miRNAs) transported by plasma exosomes, and in addition, this set allows diagnosing different variants of the disease. This new method has the advantage of providing new biomarkers that allow a rapid and reliable diagnosis of HHT, since the current methods are not valid for all the patients affected with HHT.

Method for diagnosing Hereditary Hemorrhagic Telangiectasia (HHT)

Yissum - Research Development Company of the Hebrew University posted this:

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy Dr. Zvika Granot, from the School of Medicine-IMRIC-Developmental Biology and Cancer Research, is working on a innovative approach for Neutrophil specific targeting of TGF-beta signaling as a novel anti-cancer therapy (see attached summary and several papers) Project ID : 6-2015-4241

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy

Yissum - Research Development Company of the Hebrew University posted this:

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease A New Paradigm for Combating Infectious Disease in the Age of Antibiotic Resistance. Phage Therapy offers significant advantages: 1) Natural- Harnessing nature’s own enemy against bacteria 2) Smart kinetics Phages grow with bacteria and disappear in its absence 3) Can be manipulated (unlike antibiotics) Engineered / evolutionary developed 4) Efficient against biofilm Chain reaction of the phages 5) Do not harm the microbiome Highly specific to the target pathogen. Hazan's approach for a Personalized Phage Therapy suggests an adaptive and dynamic cocktail of phages and antibiotics , that are specially tailored using AI and machine learning prediction. Hazan et.al. offer a constantly increasing “Bank” of phages. Project ID : 43-2019-10746

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease

Yissum - Research Development Company of the Hebrew University posted this:

Novel Drug Delivery System of Large Molecules for Localized Sustained Release Novel Drug Delivery System of Large Molecules for Localized Sustained Release Project ID : 6-2018-4643

Yissum - Research Development Company of the Hebrew University posted this:

Novel Chimeric System for Targeted Killing of Lymphocytic Cancer Cells Novel Chimeric Protein utilizing components of the Ubiquitin-Proteasome System for targeted killing of Lymphocytic Cancer Cells Project ID : 6-2018-4687

Yissum - Research Development Company of the Hebrew University posted this:

New Methodology to Control Calcium Carbonate Morphology and Material State New Methodology to Control Calcium Carbonate Morphology and Material State Project ID : 6-2018-4599

Yissum - Research Development Company of the Hebrew University posted this:

New Target for the Treatment of Abdominal Obesity New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway Project ID : 7-2018-4658

Yissum - Research Development Company of the Hebrew University posted this:

Novel Method for Identifying Personalized Anti-Cancer Drug Combinations NanoCode - Identifying Best Fit Cancer Drug Combinations In-Vivo Project ID : 6-2019-6704

Yissum - Research Development Company of the Hebrew University posted this:

miRNA-Responsive Drug-Loaded NMOFs for targeted Treatment of Cancer miRNA-Responsive Drug-Loaded NMOFs for targeted Treatment of Cancer Project ID : 6-2019-6706

miRNA-Responsive Drug-Loaded NMOFs for targeted Treatment of Cancer

Yissum - Research Development Company of the Hebrew University posted this:

Computational Tool for the Design of Personalized Drug Cocktails, Based on Intra-Tumor Subpopulations A computational approach to map intra-tumor subpopulations for the rational design of individualized cancer drug cocktails Project ID : 6-2019-7741

Yissum - Research Development Company of the Hebrew University posted this:

A Non-Narcotic Synergic Drug Combination for the Treatment of Severe Chronic Pain Novel synergic drug-combination for improved activation of the human opioid receptor (MOR), with expected avoidance of drug-addiction, using lower effective clinical doses Avoiding Drug Addiction Using a Novel Drug Combination for Improved Activation of the Opioid Receptor Project ID : 6-2018-5679

Yissum - Research Development Company of the Hebrew University posted this:

Synthetic Gene Circuits With Improved Safety for tumor-specific killing Synthetic Gene Circuits With Improved Safety for tumor-specific killing Project ID : 6-2019-8748

1
2
3
4
5